In the last decade, DOA clinical spectrum related to OPA1 variants has been extended to a wide variety of symptoms called DOAplus, combining deafness, ataxia, neuropathy, myopathy, Parkinsonism, and dementia [10, 18, 19]. This evidence concerns the gene OPA1 and deafness.